13 11 20

Information and support

  • Get informed
  • Get support
  • Cut my risk
  • Get involved
  • Research
  • STIMULI

    Acronym: 

    STIMULI

    ACTRN/NCT /ethics: 

    NCT02046733

    Scientific title: 

    Small cell lung carcinoma trial with nivolumab and ipilimumab in limited desease (STIMULI)

    Summary of trial and patient characteristics

    Cancer Type Lung & mesothelioma
    Trial Type Treatment
    Phase Phase II Tumour Stream Small Cell Lung Cancer
    Age Range 18 years and older Cancer Stage All stages
    Sex Both Anticipated Start Date 2014-07-28
    Molecular Target Anticipated End Date 2022-01-01
    Cancer Type Lung & mesothelioma
    Trial Type Treatment
    Phase Phase II
    Age Range 18 years and older
    Sex Both
    Molecular Target
    Tumour Stream Small Cell Lung Cancer
    Cancer Stage All stages
    Anticipated Start Date 2014-07-28
    Anticipated End Date 2022-01-01

    Trial Summary

    Despite the fact that the majority of the patients with limited disease SCLC will respond very well to the standard treatment, a great proportion will relapse within 12 - 24 months. Several studies in patients with lung cancer suggested a possible favourable association between the increased presence of immunologically active cells in the tumour and survival. Nivolumab and ipilimumab are proteins, which help your immune system to attack and destroy cancer cells by your immune cells. Early clinical trials with nivolumab and ipilimumab have shown activity in a broad range of cancers, including SCLC. The aim of the current study is to investigate the efficacy (how well the treatment works) and tolerability (how severe the side effects are) of the standard treatment (chemotherapy and radiotherapy) alone, compared with the standard treatment followed by nivolumab and ipilimumab in patients with limited SCLC.

    Lay Summary

    Small cell lung carcinoma trial with nivolumab and ipilimumab in limited desease (STIMULI)

    Sponsor / Cooperative group

    European Thoracic Oncology Platform Intergroupe Francophone de Cancerologie Thoracique Ludwig Center for Cancer Research of Lausanne Frontier Science Foundation, Hellas Bristol-Myers Squibb

    Participating Hospitals

    Hospital Clinical Trial Coordinator Email Phone Principal Investigator Recruitment Status
    Flinders Medical Centre Alex Scott-Hoy alex.scott-hoy@sa.gov.au 08 8204 4830 Shawgi Sukumaran Not Yet Recruiting